Investor Relations Roadshow Presentation by pel19120

VIEWS: 0 PAGES: 29

More Info
									Overview of Investor Relations Capabilities
Rx COMMUNICATIONS

 Specialists in the life science and
  healthcare industries

 Partner-driven -- Senior level counsel on
  EVERY account

 Partners have been through up and down
  market cycles, various political healthcare
  agendas and technology trends
Rx COMMUNICATIONS

 Experience with private and public
  companies – domestic and international

 Focused on what we do best: Investor
  Relations and Financial Media Relations

 Strong Wall Street and media contacts

 Headquartered in New York City
PRIVATE COMPANIES

Services for Private Companies
WHY EMBARK ON AN IR/PR
PROGRAM AS A PRIVATE
COMPANY?
 Lay the groundwork for future financings
  and eventual IPO

 Assist with partnering activities by building
  corporate awareness

 Build awareness of disease indications to
  generate product interest

 Align company with reputable bankers

 Become accustomed to working within
  disclosure rules i.e.; Reg FD
PROVIDING VALUE TO
PRIVATE COMPANIES

 Develop key messages positioned for
  analysts and investors

 Develop collateral materials to tell story
  integrating key messages

 Target and facilitate introductions to venture
  capitalists and institutional investors

 Target and advise on corporate finance
  team

 Target and facilitate introductions to sell-
  side analysts
PROVIDING VALUE TO
PRIVATE COMPANIES

 Build presence on the web

 Develop story ideas for the media

 Cultivate reporter interest

 Introduce to conference circuit

 Properly position company news

 Develop company disclosure policy
ACTIVITIES SUROUNDING IPO

 Assist in the selection of banking team –
  beginning of quiet period
 Press release announcing registration for
  offering
 Develop roadshow presentation
 Supplement banker’s list of target
  institutions
 Presentation training
ACTIVITIES SURROUNDING
IPO

 “Teach-ins” at banks
 Roadshow
 Press release announcing completion of
  IPO
 “Welcome letter” to new shareholders
 Create disclosure policy
 Quiet period lasts for 25 days following the
  close of IPO
PUBLIC COMPANIES

Services for Public Companies
AFTER-MARKET SUPPORT

 Need for continual dialogue with
  shareholders
 On-going targeting of investors for future
  financings
 Increase analyst coverage beyond banking
  support
 Fulfill disclosure requirements
 Crisis communications
 Strategic media out-reach
GETTING STARTED: FIRST
STEPS

 Strategy session in order to immerse
  ourselves in corporate story
 Define key message points
 Understand perceptions existent in the
  marketplace
 Create targeted list of sell-side analysts,
  venture capitalists and fund managers
GETTING STARTED: FIRST
STEPS

   Review collateral materials
   Create VIP blast e-mail/fax lists
   Develop media lists
   Design action plan
Rx COMMUNICATIONS
CAPABILITIES

   Strategic Counsel
   Roadshows
   Analyst Contact
   Investor Targeting
   Investment and Industry Conferences
   Follow-up and Analysis to Key Events
   Press Release Writing
   News Conferences/Press Briefings
   Video/Radio News Releases
   Fact Sheets
   Annual Reports
Rx COMMUNICATIONS
CAPABILITIES

   Crisis Communications
   Mergers and Acquisitions
   Positioning Strategy
   Perception Audits
   Conference Calls
   Presentation Training
   Placement Strategy
   Financial, Trade and Local Media Contacts
   Slide Presentations
   Web Site Development
THE Rx TEAM

Melody A. Carey, Co-President

 Founded Rx in 2000

 Head of Corporate Communications and
  Spokesperson, Schein Pharmaceutical, Inc.

 Director of Investor Relations,
  The Multicare Companies, Inc.

 Executive, Noonan/Russo Communications

 Former healthcare/life sciences investment
  banker, Kidder, Peabody & Co.
THE Rx TEAM

Rhonda Chiger, Co-President

 Founded Rx in 2000

 Senior Managing Director, Global
  Consulting Practice, Thomson Financial

 Managed Life Sciences departments for
  Noonan/Russo and Dewe Rogerson

 Established London office for healthcare
  investor relations firm

 Former Manager, Investor Relations,
  American Stock Exchange
The Rx Team

Eric Goldman, Vice President
 25 years experience in public relations and
  as a media relations strategist specializing
  in biotechnology, healthcare, technology
  and consumer products

 Senior Director and Vice President at
  GlobalFluency

 Handled media relations at Spector &
  Associates and Brouillard Communications,
  a division of J. Walter Thompson

 Earned 2 Silver Anvil awards for public
  relations excellence
THE Rx TEAM

Tina Posterli, Senior Media Director

 More than 14 years experience in public
  relations and marketing communications

 Handled public relations for the Tourette
  Syndrome Association

 Worked in radio, held senior positions at
  Ruder Finn Public Relations,
  Noonan/Russo Communications, March of
  Dimes and the United Way
THE Rx TEAM

Paula B. Schwartz, Senior Vice President

 Former Partner, FRB/Weber Shandwick,
  oldest and largest Investor Relations firm in
  the U.S.

 Former Vice President, ECOM Consultants,
  Inc., an investor relations firm

 Former Vice President/Director of Investor
  Relations Programs, KCS&A Public
  Relations, a public relations and investor
  relations consultancy
Rx COMMUNICATIONS
CURRENT CLIENT LIST
   Alexandria Real Estate Equities, Inc. (NYSE: ARE)
   Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)
   Amorcyte, Inc. (Private)
   Apricus Biosciences (Nasdaq: APRI)
   Bio-Path Holdings, Inc. (OTCBB: BPTH)
   Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX)
   Continucare Corporation (NYSE: CNU)
   CureFAKtor Pharmaceuticals (Private)
   Emisphere Technologies Inc. (OTCBB: EMIS)
   Glycotex, Inc. (Private)
   The Immune Tolerance Institute, Inc. (Non-Profit Organization)
   Intact Medical Corporation (Private)
   MethylGene, Inc. (TSX: MYG)
Rx COMMUNICATIONS
CURRENT CLIENT LIST
   Neovacs, SA (Alternext Paris: ALNEV)
   Nile Therapeutics, Inc. (Nasdaq: NLTX)
   Omthera Pharmaceuticals, Inc. (Private)
   PDI, Inc. (Nasdaq: PDII)
   PharmAthene, Inc. (AMEX: PIP)
   Resverlogix Corporation (TSX: RVX)
   RXi Pharmaceuticals Corporation (Nasdaq: RXII)
   Synergy Pharmaceuticals, Inc. (OTCBB: SGYP)
   TetraLogic Pharmaceuticals (Private)
   Theratechnologies (TSX: TH)
   ThromboGenics NV (Euronext Brussels: THR)
   Transdel Pharmaceuticals, Inc. (OTCBB: TDLP)
   ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP)
OURx SUCCESSES


   Helped to grow Alexion Pharmaceuticals’
    institutional shareholder base from 30% in 1996
    to approximately 95% today.

   Launched not-for-profit Immune Tolerance
    Institute resulting in broad coverage in the U.S.
    including CBS Radio Network, San Francisco
    Business Times and Drug Discovery News

   Garnered coverage for Catalyst Pharmaceutical
    Partners’ compound for cocaine addiction.
    Placements included cover stories in Newsweek,
    Scientific American Mind and NeuroInvestment
OURx SUCCESSES

   Designed and implemented IR program for
    American CareSource Holdings which led the
    company to be ranked as the number one stock
    performer on The NASDAQ Capital Market for
    2008.

   An aggressive investor outreach campaign on
    behalf of Genaissance Pharmaceuticals allowed
    Genaissance to regain compliance with
    Nasdaq’s $1 listing rule requirement.

   Guided Kos Pharmaceuticals through a failed
    marketing alliance which caused over two million
    shares to trade (four times the average daily
    trading volume) and the stock never dropped
    below 2%.
OURx SUCCESSES

   Arranged feature coverage focused on Hodgkins
    and non-Hodgkins lymphoma for MethylGene
    with Genetic Engineering News, Pink Sheet,
    BioCentury and Pharmawire

   Guided ABIOMED on issues management
    surrounding FDA panel meeting. Put FDA’s
    request for additional data into perspective with
    reporters and investors. CNBC interview key
    part of strategy.

   Implemented aggressive IR program for
    PharmAthene, Inc. which enabled the company
    to obtain coverage from two new sell-side
    analysts, garner investments from four new
    institutional funds and increase trading volume
    by three-fold within nine months.
                                        OURx SUCCESSES




    We are pleased to announce that Rx                            Rx Communications was named
Communications has been selected by PR Week                           Best Small PR Agency
               as a finalist for                       by League of American Communications Professionals
   Boutique PR Agency of the Year




                          Rx Communications Group was honored with the 2008
                         Stevie Award for Best Investor Relations Program
                                      for work on behalf of specialty
                                  pharmaceutical company, NexMed, Inc.
                                         OURx SUCCESSES




                                                               We are also pleased to share that our work for
   Rx Communications was honored with the 2002 SABRE
                                                                 ImpactRx has won an Honorable Mention
Awards Certificate of Excellence for Building a North
                                                                  Award in LACP’s (League of American
    American Investor Base for client Syngenta AG.            Communications Professionals) 2002 Publicity
                                                                       Campaign Competition.




                             Rx Communications received an honorable Mention
                          Award from PR News, as part of the PR News Platinum PR
                                 Awards 2003. The award was issued in the
                         Financial/Investor Relations category, for the company's
                             work on behalf of Genaissance Pharmaceuticals, Inc.
WHY Rx COMMUNICATIONS?

   Specialist industry knowledge and expertise
   Personal attention from Rx partners
   Decades of experience in strategic counsel and
    implementation of financial public relations
    programs
   Unique niche in working with private companies
   Well versed in IPOs, secondary offerings,
    PIPEs, venture rounds and mergers and
    acquisitions
   “The Street” knows and trusts us
  For Additional Information:
Rx Communications Group, LLC
      445 Park Avenue
          10th Floor
     New York, NY 10022
       (917) 322-2568
       www.RxIR.com

								
To top